American investors might not have to trade in the company's ADSes in the future. Trading in AstraZeneca's (NASDAQ: AZN) ...

Cambridge UK Pharma giant AstraZeneca is proving a variation on the proverbial enigma as it ponders the most appreciative ...

AstraZeneca’s chief executive has discussed shifting the company’s stock market listing to the US in a move that would deal a ...

Image source: Getty Images. Citing unidentified multiple sources, the newspaper wrote that Soriot might also be mulling a move of AstraZeneca's headquarters from the U.K. to the U.S.

AstraZeneca chief executive Sir Pascal Soriot is reportedly considering the move due to growing frustration with the UK's ...

Construction of AstraZeneca’s new global and R&D headquarters in Cambridge should have been completed last autumn – but builders are struggling to meet a revised deadline of May 2019.

Laura Earnshaw was global head of talent and development at AstraZeneca. Now she runs a Cheshire-based business dedicated to improving the mental health of children by ...

AstraZeneca boss mulls New York listing in fresh blow for City: Exodus risks transforming London into a 'global backwater' By CALUM MUIRHEAD Updated: 03:29 EDT, 2 July 2025 33 shares 146 View comments ...

It was already a bad enough week for the Prime Minister Sir Keir Starmer and the Chancellor Rachel Reeves, what with the ...

AstraZeneca’s corporate headquarters were chosen to be in London, United Kingdom, while its R&D headquarters were to be in Sweden, with major centres of excellence in the UK and USA.

Starboard Value has gained a reputation for pushing for changes such as new CEOs and cost cuts by acquiring significant ...

AstraZeneca boss Sir Pascal Soriot (pictured) is thought to be mulling shifting its listing to New York due to growing ...